A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome
A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome
This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of the drug. Eligible patients in stable condition will be randomized to receive either RO4607381 600mg po or placebo po, daily, together with a background of standard medication for ACS (including aspirin, antihypertensives and statins). The anticipated time on study treatment is 2+ years, and the target sample size is 15,600 individuals.
Inclusion Criteria:
Exclusion Criteria:
Milwaukee, Michigan 53295, United States
Salt Lake City, North Carolina 84124-1236, United States
Knoxville, South Dakota 37920, United States
CABA, C1428DCO, Argentina
Capital Federal, C1093AAS, Argentina
Ciudad Autonoma Bs As, C1280AEB, Argentina
Ciudad Autónoma de Bs. As., C1437BZK, Argentina
Sao Jose Do Rio Preto, Santa Catarina 15015-210, Brazil
Sao Jose Do Rio Preto, Santa Catarina 15015205, Brazil
Saint Georges-de-beauce, Quebec G5Y 4T8, Canada
Ste. Foy, Quebec G1V 4G5, Canada
Ostrava - Fifejdy, 72880, Czechia
Führt, 90766, Germany
Homburg/Saar, 66421, Germany
Toulouse, 31059, Grenada
S. Bonifacio, Veneto 37047, Italy
Capelle AD Yssel, 2906 ZC, Netherlands
Kuilsriver, 7580, South Africa
Lyttelton, Pretoria, 0157, South Africa
Gangwon-Do, 200-704, South Korea
Gangwon-do, 24289, South Korea
Kyonggi-do, 411-719, South Korea